The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Assessing DLL3 as a biomarker for SCLC immunotherapy
Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, discusses delta-like ligand 3 (DLL3) as a biomarker for targeted treatment of small cell lung cancer (SCLC). While the current data shows no clear correlation between DLL3 expression and response to bispecific antibody therapy, another study showed a subset of patients with extrapulmonary neuroendocrine carcinoma with high DLL3 expression benefitted from obrixtamig. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, the most obvious biomarkers are obviously looking at DLL3 itself in expression. However, the data are not yet clear. For small cell lung cancer, there doesn’t seem to be a clear-cut correlation between DLL3 expression levels and response to bispecific antibodies, neither for tarlatamab nor for rovalpituzumab. We do see a correlation between DLL3 expression levels and response in extra-pulmonary neuroendocrine carcinoma...
Well, the most obvious biomarkers are obviously looking at DLL3 itself in expression. However, the data are not yet clear. For small cell lung cancer, there doesn’t seem to be a clear-cut correlation between DLL3 expression levels and response to bispecific antibodies, neither for tarlatamab nor for rovalpituzumab. We do see a correlation between DLL3 expression levels and response in extra-pulmonary neuroendocrine carcinoma. There we’ve had a subset of the patients in the monotherapy dose escalation cohort and there it seems that only patients with a high DLL3 expression benefit from treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
